Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Bendamustine/Rituximab Represents a Backbone for Therapeutic Development in MCL

May 10th 2025

Brad S. Kahl, MD, details the evaluation of induction BR plus bortezomib with rituximab/lenalidomide maintenance in mantle cell lymphoma.

SOC Encorafenib/Binimetinib Sets a Precedent for Therapeutic Improvements in BRAF V600E–Mutant NSCLC

May 9th 2025

Joseph C. Murray, MD, highlights positive treatment shifts that have shaped the BRAF V600E–mutant non–small cell lung cancer treatment paradigm.

Adavosertib Shows Early Antitumor Activity Despite Safety Concerns in Uterine Serous Carcinoma

May 8th 2025

Adavosertib monotherapy demonstrated signs of antitumor activity in uterine serous carcinoma; however, the phase 2 starting dose was not well tolerated.

SCG101 Shows Antiviral and Antitumor Activity in Advanced HBV-Related HCC

May 8th 2025

SCG101 T-cell therapy was safe and induced sustained HBV clearance and antitumor activity in patients with advanced HBV-related hepatocellular carcinoma.

ADCs and PARP Inhibitors Are Among 2025’s Practice-Changing Agents in Ovarian Cancer

May 8th 2025

Deena M. Atieh Graham, MD, highlights the current treatment paradigm in ovarian cancer, particularly PARP inhibitors and new ADCs in the space.

Dr Kahl on the Outcomes of Bortezomib Plus BR in MCL

May 8th 2025

Brad S. Kahl, MD, details the outcomes of bortezomib plus bendamustine/rituximab in patients with mantle cell lymphoma.

Dr Gerds on the Development of Anemia in Low-Risk Myelofibrosis

May 7th 2025

Aaron Gerds, MD, details the prevalence of anemia in patients with low- to intermediate-1–risk myelofibrosis.

Dr Schmidt on FDA-Approved Bladder-Sparing Therapies in BCG-Refractory NMIBC

May 6th 2025

Bogdana Schmidt, MD, MPH, highlights FDA approved bladder-sparing therapies for patients with BCG-refractory non–muscle-invasive bladder cancer.

NIAGARA Trial Validates Perioperative Durvalumab Approach in MIBC

May 6th 2025

Petros Grivas, MD, PhD, discusses key findings from the NIAGARA trial and how these data support the use of perioperative durvalumab in MIBC management.

Nivolumab/Ipilimumab Meets Primary OS End Point in Non–Clear Cell RCC

May 5th 2025

The combination of nivolumab and ipilimumab was associated with longer 12-month OS vs standard of care in non–clear cell renal cell carcinoma.

Targeted Therapy Developments and Screening Updates Broaden the NSCLC Treatment Paradigm

May 5th 2025

Alexis Chidi, MD, PhD, MSPH, emphasizes the importance of having more available targeted therapies and explains NSCLC screening eligibility criteria.

Adjuvant CDK4/6 Inhibition Gains Further Ground in HR+/HER2– Early Breast Cancer With Ribociclib Approval

May 2nd 2025

Arielle Heeke, MD, highlights the role of adjuvant abemaciclib and ribociclib in patients with HR-positive, HER2-negative, early breast cancer.

5-Year Phase 2 Data Show 0% Recurrence Rate After Surgery Omission in Select Patients With Invasive Breast Cancer

May 2nd 2025

No recurrences, disease-free survival events, or deaths were reported in select patients with breast cancer who had surgery omitted.

Zurletrectinib Receives Priority Review from NMPA for NTRK Gene Fusion+ Advanced Solid Tumors

May 2nd 2025

A priority review was granted to zurletrectinib in China for the treatment of patients with NTRK gene fusion–positive advanced solid tumors.

sBLA Submission Planned for Epcoritamab/Rituximab/Lenalidomide in R/R FL

May 2nd 2025

An sBLA seeking the approval of epcoritamab plus rituximab and lenalidomide for relapsed/refractory FL is planned to be submitted to the FDA.

Less Is More With Advanced Surgical Approaches in Early-Stage NSCLC

May 2nd 2025

Alexis Chidi, MD, PhD, MSPH, details the evolution of surgical approaches in early-stage lung cancer, including wedge resections and segmentectomies.

Dr André on the Safety Profile of Nivolumab/Ipilimumab in MSI-H/dMMR Metastatic CRC

May 1st 2025

Thierry André, MD, discusses the safety profile of nivolumab/ipilimumab for the treatment of patients with MSI-H/dMMR metastatic colorectal cancer.

Dr Siegel on the Evaluation of Mezigdomide for R/R Myeloma

April 30th 2025

David S. Siegel, MD, explains the rationale for assessing mezigdomide—a novel thalidomide derivative—in relapsed/refractory multiple myeloma.

Subgroup Analysis Shows No Key Differences Between High-Grade Recurrence, Cancer Progression Outcomes in BCG-Unresponsive NMIBC

April 30th 2025

Among 3 subgroups of patients with BCG-unresponsive NMIBC, no significant clinical differences were identified regarding rates of high-grade recurrence.

Dr Luo on the Association Between ctDNA and Response to Daraxonrasib in RAS G12X–Mutant Advanced NSCLC

April 29th 2025

Jia Luo, MD, discusses ctDNA outcomes following treatment of daraxonrasib in ctDNA-evaluable patients with RAS G12X–mutant advanced NSCLC.